throbber
Principles of Therapy of Neurologic Disease: Nervous System Introduction: Merck Veterinary Manual
`
`10/8/16, 3:42 PM
`
`MERCK
`MANUALS
`
`4'
`
`> SEE ALL MERCK MANUALS
`Merck Manual > Veterinary Professionals > Nervous System >
`Nervous Systep Introduction
`Principles of Therapy of Neurologic Disease
`
`Also see Systemic Pharmacotherapeutics of the Nervous System.
`
`Seizure Control
`Status epilepticus (continuous or cluster seizures) in dogs and cats
`may be interrupted by diazepam, given at 0.5 mg/kg (not to exceed 10
`mg at one time), IV. Sodium pentobarbital to effect, not to exceed 3-15
`mg/kg, IV, may also be used, followed by phenobarbital at 2-4 mg/kg,
`IV, every 6 hr. A better alternative is to give propofol as a constant rate
`infusion at 0.1-0.6 mg/kg/min, followed by a loading dose of
`phenobarbital (if the animal is not already on phenobarbital) of 2-4
`mg/kg IV every 6 hr for a total of four doses. Diazepam given at 0.5-
`1.0 mg/kg/hr as a constant-rate infusion may be used to control
`persistent status epilepticus. If the animal has a preexisting hepatic
`condition that precludes the use of phenobarbital, then levetiracitam
`40-60 mg/kg may be given IV, SC,or rectally, resulting in a therapeutic
`blood level that will persist for 9 hours. Oral anticonvulsants should be
`resumed as soon as possible if currently being given.
`
`Recommended maintenance anticonvulsant therapy in dogs and cats
`is phenobarbital at 2-4 mg/kg, PO, bid, as needed to control seizures
`or to maintain serum levels at 15-40 mcg/mL. Dogs can be treated
`with potassium bromide (KBr), 22-44 mg/kg given with food until the
`serum level is 1,500-3,000 mcg/mL. Because KBr has a long half-life,
`if started at maintanance levels, the steady state therapeutic level will
`not be reached until 3 mo after initiation of therapy. Phenobarbital may
`become clinically effective in 72 hr, whereas KBr may take several
`weeks. The longterm efficacy of phenobarbital and KBr is about the
`same. However, KBr bypasses the liver, so it is better than
`phenobarbital in animals with liver disease. Animals taking
`phenobarbital often have increased liver enzymes and cholesterol
`levels but decreased thyroid levels; these should be expected and
`often do not require treatment. KBr has also been linked with
`megaesophagus and pancreatitis in dogs. Because KBr is not
`commercially available, it may be prepared by a compounding
`
`http://www.merckvetmanual.com/mvm/nervous_system/nervous_system_introduction/principles_of_therapy_of_neurologic_disease.html
`ARGENTUM Exhibit 1052
` Argentum Pharmaceuticals LLC v. Research Corporation Technologies, Inc.
`IPR2016-00204
`
`Page 1 of 4
`
`Page 00001
`
`(cid:9)
`(cid:9)
`

`
`Principles of Therapy of Neurologic Disease: Nervous System Introduction: Merck Veterinary Manual
`
`10/8/16, 3:42 PM
`
`pharmacist by mixing KBr crystals in water to give a concentration of
`250 mg/mL or by packing the crystals in gelatin capsules. KBr serum
`levels are affected by the salt content of the diet, so the diet should be
`consistent; the higher the dietary salt content, the faster the bromide is
`excreted via the kidneys. KBr has proved more efficacious than
`phenobarbital in dogs with cluster seizures and for seizures that are
`difficult to control. Phenobarbital and KBr may be given in combination.
`Diazepam is not an effective longterm oral anticonvulsant in dogs
`because of its short half-life; however, a compounding pharmacist can
`prepare rectal suppositories containing diazepam 0.5-2 mg/kg for
`home use in dogs with cluster seizures, or the injectable form can be
`given rectally at 1 mg/kg to prevent trips to emergency clinics. The
`tertiary anticonvulsants, levetiracitam and zonisamide, are quickly
`gaining greate (cid:9)
`especially has shown great efficacy
`GET
`in controlling (cid:9)
`:nimals with a poor response to
`N NEE
`O
`phenobarbital CONTENT
`KBr may cau
`recommended
`cats with unc
`however, in o
`necrosis in cat
`few weeks of
`cats; if seizur
`Acupuncture
`
`so its use in cats is no longer
`mg/kg, PO, bid, may be used in
`=:-..ause of its longer half-life in cats;
`was associated with fatal hepatic
`lose monitoring throughout the first
`I is the anticonvulsant of choice in
`oiled, then levetiracitam is added.
`of seizures in all species.
`
`THE MERCK
`> HOME HEALTH
`HANDBOOK
`
`THE MERCK MANUAL OF
`> PET HEALTH
`
`Acute Spinal Cord Injury
`Acute spinal cord injury from trauma, intervertebral disc herniation, or
`fibrocartilaginous embolization resulting in paraplegia must be treated
`aggressively in dogs to ensure the best chance for recovery. If the
`animal is seen within the first 8 hr after injury, methylprednisolone
`sodium succinate or prednisolone sodium succinate is given at 30
`mg/kg, IV, followed by 15 mg/kg in 2 and 6 hr, or a constant IV infusion
`to give a total dose of 60 mg/kg. Steroid use is not advised if it has
`been longer than 8 hr since the trauma occurred, because there may
`be more deleterious effects than beneficial ones. Dexamethasone is
`not used. Oral famotidine at 0.5-1 mg/kg, once or twice daily;
`cimetidine at 5-10 mg/kg, bid; or misoprostol at 3 mcg/kg, bid, can be
`used to protect the GI tract. Polyethylene glycol (PEG) 30% solution
`may be given IV at 2.2 mL/kg, then repeated in 24 hr. PEG is a newer
`treatment that appears promising. If the injury occurred more than 72
`hr before treatment, the benefit of PEG is questionable. For maximal
`benefit, decompressive spinal surgery should be performed as soon as
`possible, usually within 24 hr, when indicated.
`
`http://www.merckvetmanual.com/mvm/nervous_system/nervous_system_introduction/principles_of_therapy_of_neurologic_disease.html
`
`Page 2 of 4
`
`Page 00002
`
`(cid:9)
`

`
`Principles of Therapy of Neurologic Disease: Nervous System Introduction: Merck Veterinary Manual
`
`10/8/16, 3:42 PM
`
`Anti-Inflammatory Drugs
`For control of CNS inflammation in dogs and cats unassociated with a
`virus or other agent, prednisone at 2 mg/kg/day may be given PO. Oral
`famotidine at 0.5-1 mg/kg, once or twice daily; cimetidine at 5-10
`mg/kg, bid; or misoprostol at 3 mcg/kg, bid, is given to prevent GI
`irritation. If GI ulcers develop and melena is detected, sucralfate (500
`mg for cats and dogs <20 kg; 1 g for dogs >20 kg), PO, tid-qid, is given
`2 hr apart from other drugs. NSAIDs should never be given in
`conjunction with steroids, because GI ulceration is common. The
`dosages of all steroids given should be slowly tapered; abrupt
`withdrawal should be avoided. Prednisone can be used as longterm
`maintenance therapy on alternate days to avoid complete suppression
`of adrenal function. Other chemotherapeutics used for inflammatory
`CNS disease such as MUE are cytarabine (50 mg/m2, SC, bid for 2
`days, then repeated at 3-4 wk intervals), mycophenolate (10 mg/kg,
`PO, bid), and cyclosporine (5 mg/kg, PO, bid).
`
`Antiedema Drugs
`After cranial surgery and in animals with brain tumors or head injuries
`that cause a declining neurologic status, 20% mannitol, 0.5-1 g/kg,
`may be given slowly IV. Mannitol is not given in spinal cord injuries.
`Use of methylprednisolone sodium succinate as described above for
`acute spinal cord injury is no longer recommended for head injuries in
`people, and its use in the veterinary field is declining. For palliative
`treatment of brain tumors, oral prednisone may be used.
`
`Muscle Relaxants
`Diazepam at 0.5 mg/kg or methocarbamol at 40 mg/kg, PO, tid-qid,
`relieves muscle spasms from intervertebral disc protrusion and other
`sources of nerve root irritation.
`
`Antimicrobial Therapy
`Refer to discussions of specific infections for antimicrobial therapy
`recommendations.
`
`Nursing Care
`Animals with paraplegia and quadriplegia need intensive nursing care.
`The animal should be maintained on padding and turned every 4-6 hr
`to avoid decubital ulcers. The bladder must be expressed or
`catheterized every 6-8 hr. In paraplegic animals, diazepam may be
`given to facilitate relaxation of the urinary sphincter, making manual
`expression of the bladder easier. Urine must be monitored for evidence
`of cystitis. The skin must be kept clean and free of urine and feces to
`
`http://www.merckvetmanual.com/mvm/nervous_system/nervous_system_introduction/principles_of_therapy_of_neurologic_disease.html
`
`Page 3 of 4
`
`Page 00003
`
`(cid:9)
`

`
`Principles of Therapy of Neurologic Disease: Nervous System Introduction: Merck Veterinary Manual
`
`10/8/16, 3:42 PM
`
`prevent dermatitis. Quadriplegic animals may need to be hand fed
`nutritious food and given plenty of water. Manual extension and flexion
`of joints and muscle massage will help delay contractures and muscle
`atrophy in paralyzed limbs.
`
`Last full review/revision July 2013 by Thomas Schubert, DVM, DACVIM, DABVP
`
`Audio (cid:9)
`
`Figures o Photographs E Sidebars 71 Tables &Videos
`
`© 2009-2015 Merck Sharp & Dohme Corp.. a subsidiary of Merck & Co.. Inc.,
`Copyright (cid:9)
`Kenilworth. N.J.. U.S.A. Privacy Terms of Use Permissions
`
`http://www.merckvetmanual.com/mvm/nervous_system/nervous_system_introduction/principles_of_therapy_of_neurologic_disease.html (cid:9)
`
`Page 4 of 4
`
`Page 00004
`
`(cid:9)
`(cid:9)
`(cid:9)

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket